Related Experiment Video
Updated: May 29, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
Body Fat Distribution and Ectopic Fat Accumulation as Mediator of Diabetogenic Action of Lipid-Modifying Drugs: A
Yuanlong Hu1, Xinhai Cui2, Mengkai Lu3
1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Objective:
To investigate the causal relationship between various lipid-modifying drugs and new-onset diabetes, as well as the mediators contributing to this relationship.
Methods:
Mediation Mendelian randomization was performed to investigate the causal effect of lipid-modifying drug targets on type 2 diabetes (T2D) outcomes and the proportion of this association that is mediated through ectopic fat accumulation traits. Specific sets of variants in or near genes that encode 11 lipid-modifying drug targets (LDLR, HMGCR, NPC1L1, PCSK9, APOB, ABCG5/ABCG8, LPL, PPARA, ANGPTL3, APOC3, and CETP; for expansion of gene symbols, use search tool at www.genenames.org) were extracted. Random effects inverse variance weighted were performed to evaluate the causal effects among outcomes. Mediation analyses were performed to identify the mediators of the association between lipid-modifying drugs and T2D. The study was conducted from November 10, 2023, to April 2, 2024 RESULTS: The genetic mimicry of HMGCR and APOB inhibition was associated with an increased T2D risk, whereas the genetic mimicry of LPL enhancement was linked to a lower T2D risk. Gluteofemoral adipose tissue volume was a mediator for explaining 9.52% (P=.002), 16.90% (P=.03), and 10.50% (P=.003) of the total effect of HMGCR, APOB, and LPL on T2D susceptibility, respectively. Liver fat was a mediator for explaining 21.12% (P=.005), 12.28% (P=.03), and 9.84% (P=.005) of the total effect of HMGCR, APOB, and LPL on T2D susceptibility, respectively.
Conclusion:
Our findings support the hypothesis that liver fat and gluteofemoral adipose tissue play a mediating role in the prodiabetic effects of HMGCR and APOB inhibition, as well as in the antidiabetic effects of LPL enhancement.
Insights
Lipid-modifying drugs like HMGCR and APOB inhibitors increase type 2 diabetes risk, mediated by liver and gluteofemoral fat. LPL enhancers reduce risk, also mediated by these fat depots.
Area of Science:
- Genetics and Pharmacology
- Metabolic Diseases
- Causal Inference
Background:
- Lipid-modifying drugs are crucial for cardiovascular disease prevention.
- The relationship between these drugs and new-onset diabetes requires further elucidation.
- Ectopic fat accumulation is implicated in metabolic dysregulation.
Purpose of the Study:
- To investigate the causal links between lipid-modifying drug targets and type 2 diabetes (T2D).
- To identify mediating factors, specifically ectopic fat, in the drug-T2D association.
- To differentiate prodiabetic and antidiabetic effects based on drug targets.
Main Methods:
- Mediation Mendelian randomization analysis was employed.
- Genetic variants for 11 lipid-modifying drug targets were analyzed.
- Causal effects and mediation proportions were statistically evaluated.
Main Results:
- HMGCR and APOB inhibition showed a causal association with increased T2D risk.
- LPL enhancement demonstrated a causal association with reduced T2D risk.
- Liver fat and gluteofemoral adipose tissue mediated these associations.
Conclusions:
- Liver fat and gluteofemoral adipose tissue mediate the prodiabetic effects of HMGCR and APOB inhibition.
- These fat depots also mediate the antidiabetic effects of LPL enhancement.
- Findings highlight the role of fat accumulation in drug-induced diabetes risk.
More Related Videos
16:07Biochemical and High Throughput Microscopic Assessment of Fat Mass in Caenorhabditis Elegans
Published on: March 30, 2013
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Obesity
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Drug Distribution: Tissue Binding
For...
Factors Affecting Drug Distribution: Miscellaneous Factors
Age plays a significant role due to differences in body composition among different age groups. Infants, for instance, have a higher proportion of total body water and lower albumin levels, a protein that binds drugs in the bloodstream. This unique composition in infants enhances the...